Search research articles
Contact Us
Filters
Showing results (1-10 of 161) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2010
Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target
Ruth Plummer
Clinical Advances in Hematology & Oncology : H&O
|
September 10, 2015
PARP inhibitors in ovarian and other cancers
Ruth Plummer
Clinical Advances in Hematology & Oncology : H&O
|
June 19, 2012
PARP inhibitors
Ruth Plummer
Cancer Treatment and Research
|
November 17, 2023
Evolution of the Development of PARP Inhibitors
Ruth Plummer
Breast Cancer Research : BCR
|
September 3, 2011
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Ruth Plummer
Current Opinion in Pharmacology
|
June 7, 2006
Inhibition of poly(ADP-ribose) polymerase in cancer
Elizabeth Ruth Plummer
Current Opinion in Obstetrics & Gynecology
|
November 26, 2009
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer
Yvette Drew, Ruth Plummer
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
November 27, 2009
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications
Yvette Drew, Ruth Plummer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2008
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials
A Hilary Calvert, Ruth Plummer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy
Elizabeth Ruth Plummer, Hilary Calvert
Page
of 17
Search research articles
Search
Showing results (1-10 of 161) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2010
Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target
Ruth Plummer
Clinical Advances in Hematology & Oncology : H&O
|
September 10, 2015
PARP inhibitors in ovarian and other cancers
Ruth Plummer
Clinical Advances in Hematology & Oncology : H&O
|
June 19, 2012
PARP inhibitors
Ruth Plummer
Cancer Treatment and Research
|
November 17, 2023
Evolution of the Development of PARP Inhibitors
Ruth Plummer
Breast Cancer Research : BCR
|
September 3, 2011
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Ruth Plummer
Current Opinion in Pharmacology
|
June 7, 2006
Inhibition of poly(ADP-ribose) polymerase in cancer
Elizabeth Ruth Plummer
Current Opinion in Obstetrics & Gynecology
|
November 26, 2009
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer
Yvette Drew, Ruth Plummer
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
November 27, 2009
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications
Yvette Drew, Ruth Plummer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2008
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials
A Hilary Calvert, Ruth Plummer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy
Elizabeth Ruth Plummer, Hilary Calvert
Page
of 17